Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PYXSthis companyPyxis Oncology, Inc.	$1.77	-0.9×	1.34×	5.16×	-1.01×	-0.4%	82.8%	-609.2%	-574.5%	-149.1%	-117.1%	-88.9%	0.35×	-0.04×	0×	3.41×	0.0%	2	-15.92	1	C-
AVIRAtea Pharmaceuticals, Inc.	$4.40	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
CRBUCaribou Biosciences, Inc.	$0.45	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.46	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
FHTXFoghorn Therapeutics Inc.	$1.98	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
HUMAHumacyte, Inc.	$0.48	-3.69×	48.86×	74.54×	-7.48×	-105.8%	-736.5%	-5271.7%	-2003.6%	-1313.4%	-107.0%	-69.7%	20.86×	-0.65×	-9.55×	3.69×	0.0%	3	-8.67	1	D+
Peer median	—	-3.12×	1.22×	11×	-4.24×	-669.1%	67.3%	-265.6%	-240.3%	-121.2%	-63.0%	-45.4%	0.22×	-0.1×	0×	4.21×	0.0%	3	-4.44	2	—